HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Free Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (21) Citing Articles via Google Scholar Google Scholar Articles by Howell, A. Search for Related Content PubMed PubMed Citation Articles by Howell, A.

CRUK Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Manchester M20 4BX, UK

(Requests for offprints should be addressed to A Howell; Email: maria.parker{at}christie-tr.nwest.nhs.uk)

For more than 30 years, tamoxifen has been the drug of choice in treating patients with oestrogen receptor (ER)-positive breast tumours. However, research has endeavoured to develop agents that match and improve the clinical efficacy of tamoxifen, but lack its partial agonist effects. The first ‘pure’ oestrogen antagonist was developed in 1987; from this, an even more potent derivative was developed for clinical use, known as fulvestrant (ICI 182,780, ‘Faslodex’). Mechanistic studies have shown that fulvestrant possesses high ER-binding affinity and has multiple effects on ER signalling: it blocks dimerisation and nuclear localisation of the ER, reduces cellular levels of ER and blocks ER-mediated gene transcription. Unlike anti-oestrogens chemically related to tamoxifen, fulvestrant also helps circumvent resistance to tamoxifen. There are extensive data to support the lack of partial agonist effects of fulvestrant and, importantly, its lack of cross-resistance with tamoxifen. In phase III studies in patients with locally advanced or metastatic breast cancer, fulvestrant was at least as effective as anastrozole in patients with tamoxifen-resistant tumours, was effective in the first-line setting and was also well tolerated. These data are supported by experience from the compassionate use of fulvestrant in more heavily pretreated patients. Further studies are now underway to determine the best strategy for sequencing oestrogen endocrine therapies and to optimise dosing regimens offulvestrant. At present, and for the foreseeable future, fulvestrant is the only oestrogen antagonist with no agonistic effects licensed for the treatment of advanced breast cancer in postmenopausal women. Other similar oestrogen antagonists are undergoing research and development, with a few currently being evaluated in phase II trials.

This article has been cited by other articles:

				T. van Agthoven, A. M Sieuwerts, D. Meijer, M. E Meijer-van Gelder, T. L A van Agthoven, R. Sarwari, S. Sleijfer, J. A Foekens, and L. C J Dorssers Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response Endocr. Relat. Cancer, February 18, 2010; 17(1): 215 - 230. [Abstract] [Full Text] [PDF]

				M. C. Zimmermann, S. L. Tilghman, S. M. Boue, V. A. Salvo, S. Elliott, K. Y. Williams, E. V. Skripnikova, H. Ashe, F. Payton-Stewart, L. Vanhoy-Rhodes, et al. Glyceollin I, a Novel Antiestrogenic Phytoalexin Isolated from Activated Soy J. Pharmacol. Exp. Ther., January 1, 2010; 332(1): 35 - 45. [Abstract] [Full Text] [PDF]

				A. Pedram, M. Razandi, A. J. Evinger, E. Lee, and E. R. Levin Estrogen Inhibits ATR Signaling to Cell Cycle Checkpoints and DNA Repair Mol. Biol. Cell, July 15, 2009; 20(14): 3374 - 3389. [Abstract] [Full Text] [PDF]

				P. Kumar, A. Kamat, and C. R. Mendelson Estrogen Receptor {alpha} (ER{alpha}) Mediates Stimulatory Effects of Estrogen on Aromatase (CYP19) Gene Expression in Human Placenta Mol. Endocrinol., June 1, 2009; 23(6): 784 - 793. [Abstract] [Full Text] [PDF]

				B. Zhang, H. Li, R. B. Riggins, M. Zhan, J. Xuan, Z. Zhang, E. P. Hoffman, R. Clarke, and Y. Wang Differential dependency network analysis to identify condition-specific topological changes in biological networks Bioinformatics, February 15, 2009; 25(4): 526 - 532. [Abstract] [Full Text] [PDF]

				F. Yasuhara, G. R. O. Gomes, E. R. Siu, C. I. Suenaga, E. Marostica, C. S. Porto, and M. F. M. Lazari Effects of the Antiestrogen Fulvestrant (ICI 182,780) on Gene Expression of the Rat Efferent Ductules Biol Reprod, September 1, 2008; 79(3): 432 - 441. [Abstract] [Full Text] [PDF]

				M. Honorat, A. Mesnier, J. Vendrell, J. Guitton, I. Bieche, R. Lidereau, G. D Kruh, C. Dumontet, P. Cohen, and L. Payen ABCC11 expression is regulated by estrogen in MCF7 cells, correlated with estrogen receptor {alpha} expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells Endocr. Relat. Cancer, March 1, 2008; 15(1): 125 - 138. [Abstract] [Full Text] [PDF]

				V. C. Jordan Estrogen Receptors in BRCA1-Mutant Breast Cancer: Now You See Them, Now You Don't J Natl Cancer Inst, November 21, 2007; 99(22): 1655 - 1657. [Full Text] [PDF]

				A. M. Trauernicht, S. J. Kim, N. H. Kim, and T. G. Boyer Modulation of Estrogen Receptor {alpha} Protein Level and Survival Function by DBC-1 Mol. Endocrinol., July 1, 2007; 21(7): 1526 - 1536. [Abstract] [Full Text] [PDF]